IPO8

Across TCGA pan-cancer cohorts, IPO8 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IPO8 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IPO8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IPO8 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

HNSC, CCRCC, and GBM are the cancer types where IPO8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.582	0.914	.002	36	view →
CCRCC	OS	Median	III,IV	0.527	0.865	.003	22	view →
GBM	OS	Median	All	0.677	0.413	.002	9	view →
UCEC	DFS	Median	All	0.934	1.000	.018	8	view →
PDAC	OS	Tertile	All	0.478	0.761	.024	5	view →
LSCC	OS	Quartile	III,IV	0.918	0.591	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IPO8–HNSC (OS)

Open the HNSC breakdown →